Literature DB >> 1647246

A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes.

Y Gozes1, D E Brenneman, M Fridkin, R Asofsky, I Gozes.   

Abstract

Vasoactive intestinal peptide (VIP) is a neuropeptide which also interacts with cells of the immune system. The paucity of specific VIP receptor antagonists has hampered studies of possible receptor heterogeneity and of VIP function. To aid in achieving these goals, a new VIP antagonist, a hybrid between neurotensin and VIP, has been synthesized. This peptide interacted with VIP receptors on spinal cord cells with an affinity 10-fold greater than VIP itself. In contrast, 1000-fold higher concentrations of the antagonist were required to displace labeled VIP from its receptor on lymphoid cells as compared to VIP itself, suggesting VIP receptor heterogeneity between immune and spinal cord cells.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1647246     DOI： 10.1016/0006-8993(91)90528-4

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  14 in total

1.  VIP, from gene to behavior and back: summarizing my 25 years of research.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

2.  Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-induced colitis in mice.

Authors:  John P Vu; Mulugeta Million; Muriel Larauche; Leon Luong; Joshua Norris; James A Waschek; Charalabos Pothoulakis; Joseph R Pisegna; Patrizia M Germano
Journal:  J Mol Neurosci       Date:  2014-01-07       Impact factor: 3.444

3.  VIP blockade leads to microcephaly in mice via disruption of Mcph1-Chk1 signaling.

Authors:  Sandrine Passemard; Vincent El Ghouzzi; Hala Nasser; Catherine Verney; Guilan Vodjdani; Adrien Lacaud; Sophie Lebon; Marc Laburthe; Patrick Robberecht; Jeannette Nardelli; Shyamala Mani; Alain Verloes; Pierre Gressens; Vincent Lelièvre
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

Review 4.  A VIP hybrid antagonist: from developmental neurobiology to clinical applications.

Authors:  I Gozes; M Fridkin; D E Brenneman
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

5.  Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain.

Authors:  P Gressens; S Marret; J M Hill; D E Brenneman; I Gozes; M Fridkin; P Evrard
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

Review 6.  VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment.

Authors:  J M Muller; V Lelievre; L Becq-Giraudon; A C Meunier
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

Review 7.  Neuropeptides as growth and differentiation factors in general and VIP in particular.

Authors:  I Gozes; D E Brenneman
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

8.  Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene.

Authors:  I Gozes; J Glowa; D E Brenneman; S K McCune; E Lee; H Westphal
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

9.  Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse.

Authors:  P Gressens; J M Hill; B Paindaveine; I Gozes; M Fridkin; D E Brenneman
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

10.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

Authors:  T W Moody; F Zia; M Draoui; D E Brenneman; M Fridkin; A Davidson; I Gozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.